Purpose: Bacillus Calmette-Guérin (BCG) intravesical therapy is the standard treatment in high-risk patients with non-muscle-invasive bladder cancer, but a significant number of patients experience recurrence after BCG therapy. Although several treatment options are available for recurrence after BCG therapy, the optimal treatment strategy is still controversial. We reviewed current and promising treatment options after BCG failure. Materials and Methods: A search of published literature using PubMed and meeting abstracts was performed. Results: BCG failures are further subdefined as BCG refractory, BCG resistant, BCG relapsing, and BCG intolerance. Several predictors for BCG response have been studied, but prediction or stratification before therapy seems to be difficult in clinical practice. Novel biomarkers associated with immunologic mechanisms appear to be promising to predict BCG failure. Radical cystectomy is the standard treatment for BCG-refractory disease, but the timing of cystectomy is controversial. BCG maintenance or combination with interferon-α is a promising therapy for BCG resistance or relapse. Some salvage therapies or device-assisted instillations have been also promising, but the efficacy and safety of these novel therapies should be confirmed by large prospective studies before their clinical use in BCG failure. Conclusions: Patients with BCG failure are not a homogeneous group and need to be stratified. Radical cystectomy should be performed without delay in patients with BCG-refractory status, but salvage intravesical therapies may be an alternative in cases without true refractory status. Although BCG and interferon intravesical therapy is promising, more efficient salvage therapy after BCG failure is required. (Korean J Urol 2009;50:1037-1047)
INTRODUCTION
Since bacillus Calmette-Guérin (BCG) was first used in humans in 1921, its main use has been for vaccination against tuberculosis [1] . However, BCG has also been used in the immunotherapy of cancer or chronic inflammation. Until now, BCG was the most frequently used immunotherapeutic treatment. Morales et al. investigated a new form of application for BCG in 1976 [2] . They developed a schedule for the effective adjuvant intravesical treatment of non-muscle-invasive bladder cancer (NMIBC) after transurethral resection (TUR) with BCG.
Since the late 1980s, evidence has become available that instillation of BCG into the bladder is an effective form of immunotherapy in NMIBC. Recent meta-analyses have confirmed that BCG after TUR is superior to TUR alone or to TUR and chemotherapy in preventing recurrence [3] [4] [5] . To date, BCG intravesical therapy 
BCG-intolerent
Failure to achieve disease-free state by 6 months after initial BCG therapy with either maintenance or retreatment at 3 months due to either persistent or rapidly recurring disease. Also includes any progression in stage, grade, or disease extent by 3 months after first cycle of BCG Recurrence or persistence at 3 months after the induction cycle but of lesser degree, stage, or grade which is no longer present at 6 months from BCG retreatment and/or TUR Recurrence of disease after achieving a disease-free status by 6 months. Relapse is further defined by time of recurrence: Early: within 12 months Intermediate: 12-24 months Late: ＞24 months Caution: relapsing disease while on active maintenance (within 3 months) may qualify as BCG refractory Disease recurrence after a less than adequate course of therapy is applied due to a serious adverse event or symptomatic intolerance that mandates discontinuation of further BCG.
BCG: bacillus Calmette-Guérin, TUR: transurethral resection is the standard treatment in high-risk patients with NMIBC and in patients with carcinoma in situ (CIS) [6] [7] [8] . However, although BCG is the most effective therapy for preventing recurrence and progression in NMIBC, a significant number of patients do experience recurrence and progression after BCG therapy. The treatment fails in 30-40% of patients, and 30-40%
of those who initially responded relapse. This status has been generally called "BCG failure" [9] . Several treatment options for recurrence after BCG therapy are available. Radical cystectomy or salvage intravesical therapy can be selectively chosen as the treatment of BCG failure according to disease status. Currently, several agents or treatment protocols are now being investigated for overcoming BCG failure. However, the optimal treatment strategy of BCG failure is still controversial. Therefore, in this article, we review current and promising treatment options after BCG failure.
DEFINITION OF BCG FAILURE
Although BCG failure is a generally used term for recurrence after BCG therapy in bladder cancer, its definition is not clear. 
PREDICTION OF BCG FAILURE
Several studies have investigated the factors predictive of the BCG response in NMIBC. Although some studies have reported the potential prediction of recurrence or progression after BCG, after more than two decades of study, no independent prognostic factor for remission or relapse after BCG therapy appears to have been identified [18] . However, recent studies have reported novel predictive factors.
Demographic predictors
Recent multivariate analyses based on large, multicenter bladder cancer patient cohorts of greater than 1,000 patients have suggested some independent predictors for recurrence and progression after BCG induction and short-term maintenance treatment [19] . Analysis from a Spanish group with 1,062 patients with NMIBC suggested that female gender, history of recurrence, multiplicity, and presence of CIS are predictors for recurrence, and age, history of recurrence, high grade, T1 stage, and recurrence at initial cystoscopy are predictors for progression [19] .
T1 substaging
Microstaging of T1 tumors may help to select tumors with a higher risk of progression. Several reports in the past 10 years have demonstrated a worse prognosis for T1 tumors with deep lamina propria invasion, with progression rates ranging from 29% to 55% [20] [21] [22] . Subgrouping of T1 tumors uses the muscularis mucosa as a landmark of microstaging. According to the muscularis mucosa, T1 tumors are classified into T1a when the tumor involves the subepithelial connective tissue superficial to the muscularis mucosa, T1b when it goes into the level of the muscularis mucosa, and T1c when it goes beyond the muscularis mucosa [21] . In a study of 49 patients with T1
bladder cancer, Kondylis et al showed that substaging of T1 tumors did not affect response to BCG regarding recurrence or progression [20] . In contrast, Orsola et al reported that patients with high-grade T1 bladder cancer invading the muscularis mucosa (T1b) had a seven times higher risk of a positive repeat TUR at 3 months after the initial TUR and BCG therapy if the initial tumor was greater than 3 cm and a five-fold increased risk if associated with CIS [21, 22] . However, this result has not been confirmed in a prospective study.
Tumor markers
Tumor marker expression has been investigated as a predictive factor for recurrence or progression in several cancers with various stages and has also been investigated in bladder cancer treated with BCG, but the results have been inconsistent.
Some investigators reported that P53 and Ki-67 protein overexpression are independent predictors for recurrence in NMIBC treated with BCG [23, 24] , but others have reported no significant associations [25] [26] [27] [28] . The results for ezrin protein expression were similarly inconsistent [24, 27, 29] . Recently, pRb was proposed as a predictive factor of nonresponse and recurrence after BCG plus IFN-α [28] . However, because these markers have not been confirmed by a prospective study, debate about these issues remains.
Cytokines
Various cytokines or cytokine-related parameters have been investigated as a predictive or prognostic factor in NMIBC treated with BCG. These include cytokine gene polymorphisms, tumor necrosis factor-alpha gene, antigen-presenting molecules and chemokines, T helper 1 and 2 lymphocyte urinary cytokine profiles, and urinary interleukin-8 [30] [31] [32] [33] [34] [35] . Some reports have
shown promising results for cytokines as the predictive factor of BCG response or prognosis, but despite decades of investigation, there are still no molecular markers that predict response to BCG. cancer cell-to-lamina propria TAM ratio [36] . In that study, higher cancer cell TAM counts and higher cancer cell-to-lamina propria TAM ratio were independent prognostic factors for recurrence after BCG. Ayari et al performed a similar study with TAMs and tumor-infiltrating dendritic cells (TIDCs) [37] .
Immune cells

They demonstrated that a high level of infiltration by CD83
(＋) TIDCs or CD68 (＋) TAMs does not respond as well to BCG immunotherapy. These two studies emphasize the 
TREATMENT OPTIONS AFTER BCG FAILURE
Patients with T1G3 bladder cancer have a markedly varied potential for tumor progression, whereas more than a third do not experience recurrence or progression. Radical cystectomy may be the best treatment in high-risk patients but is an overtreatment in patients who will have no recurrence or progression. Therefore, patient selection might be important to manage patients who fail BCG therapy. Several salvage therapies after failure of BCG have been studied, and some therapies have shown promising results as second-line intravesical therapy after BCG.
Radical cystectomy
Currently, radical cystectomy with pelvic lymph node dissection is the standard treatment for patients who have failed BCG. This treatment provides a good 5-year survival rate of 70-90%, and orthotopic neobladder reconstruction has been established as the standard procedure that provides good quality of life [10, 38] . However, cystectomy yields a 2-3% mortality rate and 20-30% complication rates. Some patients who undergo cystectomy may suffer when adjusting to postoperative changes in their quality of life. Early cystectomy would be an overtreatment, even in high-risk patients, because more than one third of T1G3 bladder cancer patients do not experience recurrence or progression.
The most debatable issue is when cystectomy should be performed [38] . No prospective randomized trial has evaluated the optimal timing of cystectomy in these patients. The timing of cystectomy is an important prognostic factor. Several studies have emphasized the risk of delayed cystectomy in high-risk NMIBC. One study of BCG plus interferon-α (IFN-α) in 1,106 NMIBC patients suggested that the timing of BCG failure is a significant predictor for subsequent recurrence [39] . In that study, patients with disease recurrence more than 1 year after BCG treatment and who were treated with low-dose BCG plus interferon-alpha had response rates similar to those of BCGnaïve patients treated with regular-dose BCG plus interferon ( Fig. 1 ) [39] . From this result, the authors suggested that patients with BCG failure more than 1 year after BCG might benefit from another trial with intravesical immunotherapy, whereas patients with recurrence within 1 year of BCG should be considered for either cystectomy or alternative intravesical therapies. In addition, a recent historical comparative study suggested that a paradigm shift has occurred because patients are increasingly offered radical cystectomy before disease progression to muscle invasion [40] . As a result, the diseasespecific death of the contemporary cohort in which preemptive radical cystectomy was performed was less than that of the historical cohort in which the bladder was preserved until progression to muscle invasion [40] . Another study demonstrated that patients who underwent surgery less than 2 years after initial transurethral resection of bladder tumor (TURBT)
for high-risk NMIBC had a significantly improved survival compared with similar patients who had surgery after 2 years [41] [42] [43] . Herr et al have suggested that tumor response at 6 months was the most important factor for predicting ultimate failure and progression [42] . Therefore, it is recommended that cystectomy should not be delayed in high-risk patients beyond 6 months (two courses of BCG) [38] . after a second course of BCG [44, 45] . Therefore, patients
should not be considered a true failure if they have received only one course of BCG. Another course of BCG can be applied to these patients, whereas patients who have evidence of disease after two courses are unlikely to respond to additional BCG therapy and are at risk for progression of disease [10] . These patients, who were classified as BCG refractory, are "true BCG failures" and treatment options other than BCG should be considered. Patients who delay definitive therapy by receiving two doses of initiation therapy or an alternative treatment for BCG-refractory disease may be at increased risk for progression with a proportionate decrease in long-term survival and, therefore, early cystectomy is the best choice of treatment in these patients [10, 17, 38, 41] .
Although the merits of a maintenance course have been debated in the past, BCG maintenance is highly recommended as the standard adjuvant treatment in high-risk NMIBC [10] .
With increasing data showing its benefits, a maintenance course of BCG at 3 months is currently accepted. Meta-analyses showed that induction BCG followed by maintenance BCG decreases recurrence in high-risk patients, although most patients did not complete the entire course to 36 months [46, 47] . However, Herr pointed to the bias included in these meta-analyses, which exaggerated the efficacy of BCG maintenance, and insisted that critical analysis of the evidence does not support the liberal use of maintenance BCG as currently practiced and recommended [48] . Herr suggested that maintenance BCG does not appear superior to initial BCG treatment in preventing or delaying tumor progression and that prolonged BCG treatment adds toxicity [48] . However, the decision for maintenance of BCG after BCG failure must depend on disease status. BCG maintenance is not optimal in patients with BCG-refractory status, but is recommended as the adjuvant treatment after an additional BCG induction course in patients with BCG resistance or relapse, or even in patients with BCG-intolerance.
2) BCG plus interferon-α: Interest in interferon as an intravesical agent against bladder cancer developed in the 1980s [41] . Results of early prospective series with interferon were disappointing. The long-term success rate of IFN-α monotherapy of BCG failures is generally less than 15% [49] .
Furthermore, one study of IFN-α found it to be no better than water placebo at 43 months of follow-up, which suggests that it has no role in recurrent stage T1 disease [50] . However, over the subsequent decade, sufficient experience with both agents accumulated to suggest using them together as salvage therapy in patients with recurrence after intravesical BCG. A large, national, multicenter phase II trial assessed the efficacy of the combination of BCG and interferon [51] . This trial showed that this combination therapy is well tolerated and appears to prolong the disease-free interval in previous BCGfailure patients. With a median follow-up of 24 months, 45%
of BCG failures remained recurrence-free compared with 59%
in the BCG-naïve group treated with a normal dose of BCG (Fig. 2) . Although the definition of BCG failure was quite liberal and included some BCG-intolerant patients, this trial showed that the combination of BCG and IFN seems a promising second-line immunotherapy regimen after BCG failures, but the results of this phase II trial should be confirmed [10] .
Salvage intravesical chemotherapy
Several intravesical drugs have been investigated in high-risk patients who failed BCG. Conventional intravesical chemotherapeutic agents have been investigated in a few studies but did not show satisfactory efficacy. Platinum derivatives have been tried but were generally too irritating and associated with occasional fatal anaphylaxis [52] . Recently, two newer cytotoxic chemotherapeutic drugs, gemcitabine and docetaxel, with known systemic activity against advanced bladder cancer have (50%) had an initial complete response [62] . These studies have confirmed the potential of gemcitabine in these patients.
However, in the largest most dose-intensive regimen with the longest follow-up, the 1-year complete response rate was only 21%, suggesting that single-agent gemcitabine will not likely meet its role as a universal salvage drug [14] . 4) Docetaxel: Docetaxel is a chemotherapeutic agent that has recently been investigated for intravesical therapy. A phase I trial showed that docetaxel is safe for intravesical therapy in patients with BCG-refractory NMIBC, with no systemic absorption and limited toxicity. Of the 18 patients, 56% had no evidence of disease at the cystoscopy and biopsy after treatment, and 22% remained disease free during the median 32.5 months of follow-up [63] . There has been no phase II trial, but recently, an extended report for intravesical docetaxel was made by the same group [64] . In that study, monthly maintenance therapy with intravesical docetaxel was performed in 13 patients with BCG refractory Ta, T1, or CIS to overcome the low durability in the previous study. With a median 13 months of follow-up, 10 of 13 patients had a complete response after induction, and 6 have remained disease-free. All 10 responders completed at least three instillations of maintenance, of whom 6 have remained recurrence-free. In summary, intravesical docetaxel is tolerable and has shown promising results in patients with BCG failures, but a phase II study should be performed to confirm its efficacy. 5) Combination therapy: Although multi-agent chemotherapy has become universal for almost all cases of systemic chemotherapy, previous attempts to use combined or alternating older chemotherapy drugs, such as adriamycin and mitomycin, intravesically were frustrated by severe cystitis despite some evidence of enhanced activity [14] . However, combinations of drugs in which one or both are non-vesicants may be better received [14] . One such combination of immediate sequential gemcitabine followed by mitomycin reported a near 50%
recurrence-free rate in 27 BCG refractory patients at 18 months compared with 20% for gemcitabine alone in 12 similar patients [65] . Further prospective studies with combinations of other intravesical chemotherapeutic agents including gemcitabine and docetaxel deserve to be carried out.
Device-Assisted instillations
Although intravesical chemotherapy is not a standard electromotive MMC in high-risk patients [67] . In that study, 212 patients with pT1 bladder cancer were randomly assigned to conventional BCG induction cycle or to BCG followed by electromotive MMC once per week for three cycles followed by maintenance treatment. Patients assigned sequential BCG and electromotive MMC had a higher disease-free interval and lower recurrence than did patients assigned BCG alone [67] . [54, 68] . Thermochemotherapy has also been reported to be successful in BCG failures [69, 70] . 
Chemoradiation therapy
Recently, the Harvard Radiation Oncology Group reported their experiences of bladder-sparing trimodality therapy in high-risk NMIBC patients who have progressed to muscleinvasive disease [75] . The bladder-intact survival rate at 3, 5, and 7 years was 61%, 54%, and 54%, respectively. Although this was a small retrospective study, their favorable results suggest that concurrent chemoradiation therapy can be used in the management of high-risk T1 bladder cancer. However, there has been no study of chemoradiation therapy in BCG failure patients. 
CONCLUSIONS
